{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:49:30Z","timestamp":1791978570580,"version":"4.4.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA244719 to J.Q."],"award-info":[{"award-number":["U54CA244719 to J.Q."]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA244719 to B.D.S"],"award-info":[{"award-number":["U54CA244719 to B.D.S"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA266146 to B.D.S."],"award-info":[{"award-number":["R01CA266146 to B.D.S."]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI192499 to J.Q."],"award-info":[{"award-number":["R01AI192499 to J.Q."]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI190103 to T.W."],"award-info":[{"award-number":["R01AI190103 to T.W."]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI192499 to T.W."],"award-info":[{"award-number":["R01AI192499 to T.W."]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP230363 to T.W."],"award-info":[{"award-number":["RP230363 to T.W."]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77461-9","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:33:23Z","timestamp":1789223603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor-targeted IL-10 synergizes with IL-2 to enhance antitumor immunity while minimizing immune-related adverse events"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7837-8407","authenticated-orcid":false,"given":"Zhichen","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5709-4129","authenticated-orcid":false,"given":"Yifei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-4388","authenticated-orcid":false,"given":"Baran D.","family":"Sumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4355-149X","authenticated-orcid":false,"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5228-2906","authenticated-orcid":false,"given":"Jian","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"77461_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/j.seminoncol.2015.05.015","volume":"42","author":"T Floros","year":"2015","unstructured":"Floros, T. & Tarhini, A. A. Anticancer cytokines: biology and clinical effects of interferon-\u03b12, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol. 42, 539\u2013548 (2015).","journal-title":"Semin Oncol."},{"key":"77461_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158\u2013168 (2018).","journal-title":"N. Engl. J. Med."},{"key":"77461_CR3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","volume":"40","author":"KE Pauken","year":"2019","unstructured":"Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H. & Sharpe, A. H. Adverse events following cancer immunotherapy: obstacles and opportunities. Trends Immunol. 40, 511\u2013523 (2019).","journal-title":"Trends Immunol."},{"key":"77461_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","volume":"19","author":"KW Moore","year":"2001","unstructured":"Moore, K. W., de Waal Malefyt, R., Coffman, R. L. & O\u2019Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683\u2013765 (2001).","journal-title":"Annu. Rev. Immunol."},{"key":"77461_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nri2711","volume":"10","author":"M Saraiva","year":"2010","unstructured":"Saraiva, M. & O\u2019Garra, A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10, 170\u2013181 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"77461_CR6","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.immuni.2019.03.020","volume":"50","author":"W Ouyang","year":"2019","unstructured":"Ouyang, W. & O\u2019Garra, A. IL-10 Family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity 50, 871\u2013891 (2019).","journal-title":"Immunity"},{"key":"77461_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101325","volume":"44","author":"M Oft","year":"2019","unstructured":"Oft, M. Immune regulation and cytotoxic T cell activation of IL-10 agonists - Preclinical and clinical experience. Semin. Immunol. 44, 101325 (2019).","journal-title":"Semin. Immunol."},{"key":"77461_CR8","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41423-020-0481-0","volume":"17","author":"J Qiao","year":"2020","unstructured":"Qiao, J. & Fu, Y. X. Cytokines that target immune killer cells against tumors. Cell Mol. Immunol. 17, 722\u2013727 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"77461_CR9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.trecan.2023.05.003","volume":"9","author":"MA Salkeni","year":"2023","unstructured":"Salkeni, M. A. & Naing, A. Interleukin-10 in cancer immunotherapy: from bench to bedside. Trends Cancer 9, 716\u2013725 (2023).","journal-title":"Trends Cancer"},{"key":"77461_CR10","doi-asserted-by":"crossref","unstructured":"Zhao, Y. et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat. Biotechnol. 42, 1693\u20131704 (2024).","DOI":"10.1038\/s41587-023-02060-8"},{"key":"77461_CR11","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00262-011-1104-5","volume":"60","author":"CM Wilke","year":"2011","unstructured":"Wilke, C. M. et al. Dual biological effects of the cytokines interleukin-10 and interferon-\u03b3. Cancer Immunol. Immunother. 60, 1529\u20131541 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"77461_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ccr.2011.11.003","volume":"20","author":"JB Mumm","year":"2011","unstructured":"Mumm, J. B. et al. IL-10 elicits IFN\u03b3-dependent tumor immune surveillance. Cancer Cell 20, 781\u2013796 (2011).","journal-title":"Cancer Cell"},{"key":"77461_CR13","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2016.68.1106","volume":"34","author":"A Naing","year":"2016","unstructured":"Naing, A. et al. Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J. Clin. Oncol. 34, 3562\u20133569 (2016).","journal-title":"J. Clin. Oncol."},{"key":"77461_CR14","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","volume":"34","author":"A Naing","year":"2018","unstructured":"Naing, A. et al. PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8(+) T cell invigoration and polyclonal T cell expansion in cancer patients. Cancer Cell 34, 775\u2013791 (2018).","journal-title":"Cancer Cell"},{"key":"77461_CR15","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/S1470-2045(19)30514-5","volume":"20","author":"A Naing","year":"2019","unstructured":"Naing, A. et al. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 20, 1544\u20131555 (2019).","journal-title":"Lancet Oncol."},{"key":"77461_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jtho.2020.10.001","volume":"16","author":"D Spigel","year":"2021","unstructured":"Spigel, D. et al. Randomized phase 2 studies of checkpoint inhibitors alone or in cCombination with pegilodecakin in patients with metastatic NSCLC (CYPRESS 1 and CYPRESS 2). J. Thorac. Oncol. 16, 327\u2013333 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"77461_CR17","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.ccell.2019.05.005","volume":"35","author":"J Qiao","year":"2019","unstructured":"Qiao, J. et al. Targeting tumors with IL-10 prevents dendritic cell-mediated CD8(+) T cell apoptosis. Cancer Cell 35, 901\u2013915 (2019).","journal-title":"Cancer Cell"},{"key":"77461_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","volume":"38","author":"W Liao","year":"2013","unstructured":"Liao, W., Lin, J. X. & Leonard, W. J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38, 13\u201325 (2013).","journal-title":"Immunity"},{"key":"77461_CR19","doi-asserted-by":"publisher","unstructured":"Ren, Z. et al. Selective delivery of low-affinity IL-2 to PD-1\u2009+ T cells rejuvenates antitumor immunity with reduced toxicity. J. Clin. Invest 132, https:\/\/doi.org\/10.1172\/jci153604 (2022).","DOI":"10.1172\/jci153604"},{"key":"77461_CR20","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/s41556-022-01024-5","volume":"24","author":"J Bae","year":"2022","unstructured":"Bae, J. et al. IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8(+) T cells to overcome immunotherapy resistance in cancer. Nat. Cell Biol. 24, 1754\u20131765 (2022).","journal-title":"Nat. Cell Biol."},{"key":"77461_CR21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","volume":"12","author":"AV Maker","year":"2005","unstructured":"Maker, A. V. et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I\/II study. Ann. Surg. Oncol. 12, 1005\u20131016 (2005).","journal-title":"Ann. Surg. Oncol."},{"key":"77461_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-019-0522-3","volume":"7","author":"EI Buchbinder","year":"2019","unstructured":"Buchbinder, E. I. et al. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J. Immunother. Cancer 7, 49 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"77461_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40425-019-0567-3","volume":"7","author":"M Fishman","year":"2019","unstructured":"Fishman, M. et al. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry. J. Immunother. Cancer 7, 84 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"77461_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11782-w","volume":"10","author":"Z Sun","year":"2019","unstructured":"Sun, Z. et al. A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8(+) T-cell response and effective tumor control. Nat. Commun. 10, 3874 (2019).","journal-title":"Nat. Commun."},{"key":"77461_CR25","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-15-1412","volume":"6","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. Autocrine complement inhibits IL10-dependent T-cell-mediated antitumor immunity to promote tumor progression. Cancer Discov. 6, 1022\u20131035 (2016).","journal-title":"Cancer Discov."},{"key":"77461_CR26","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1158\/0008-5472.CAN-12-0721","volume":"72","author":"J Emmerich","year":"2012","unstructured":"Emmerich, J. et al. IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res. 72, 3570\u20133581 (2012).","journal-title":"Cancer Res."},{"key":"77461_CR27","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1182\/blood-2010-08-301507","volume":"117","author":"E Billerbeck","year":"2011","unstructured":"Billerbeck, E. et al. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2R\u03b3(null) humanized mice. Blood 117, 3076\u20133086 (2011).","journal-title":"Blood"},{"key":"77461_CR28","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.pharmthera.2005.05.002","volume":"108","author":"K Chiba","year":"2005","unstructured":"Chiba, K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharm. Ther. 108, 308\u2013319 (2005).","journal-title":"Pharm. Ther."},{"key":"77461_CR29","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/s43018-023-00600-4","volume":"4","author":"EC Lerner","year":"2023","unstructured":"Lerner, E. C. et al. CD8(+) T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis. Nat. Cancer 4, 1258\u20131272 (2023).","journal-title":"Nat. Cancer"},{"key":"77461_CR30","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","volume":"26","author":"B Ruffell","year":"2014","unstructured":"Ruffell, B. et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26, 623\u2013637 (2014).","journal-title":"Cancer Cell"},{"key":"77461_CR31","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638\u2013652 (2014).","journal-title":"Cancer Cell"},{"key":"77461_CR32","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711\u2013723 e714 (2017).","journal-title":"Cancer Cell"},{"key":"77461_CR33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrc1586","volume":"5","author":"W Zou","year":"2005","unstructured":"Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263\u2013274 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"77461_CR34","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/cac2.12596","volume":"44","author":"J Chen","year":"2024","unstructured":"Chen, J., Duan, Y., Che, J. & Zhu, J. Dysfunction of dendritic cells in tumor microenvironment and immunotherapy. Cancer Commun. (Lond.) 44, 1047\u20131070 (2024).","journal-title":"Cancer Commun. (Lond.)"},{"key":"77461_CR35","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","volume":"56","author":"F Bayerl","year":"2023","unstructured":"Bayerl, F. et al. Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. Immunity 56, 1341\u20131358 e1311 (2023).","journal-title":"Immunity"},{"key":"77461_CR36","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nm.2365","volume":"17","author":"SC Wuest","year":"2011","unstructured":"Wuest, S. C. et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 17, 604\u2013609 (2011).","journal-title":"Nat. Med."},{"key":"77461_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/intimm\/10.2.237","volume":"10","author":"V Kronin","year":"1998","unstructured":"Kronin, V., Vremec, D. & Shortman, K. Does the IL-2 receptor alpha chain induced on dendritic cells have a biological function? Int. Immunol. 10, 237\u2013240 (1998).","journal-title":"Int. Immunol."},{"key":"77461_CR38","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","volume":"22","author":"Y Guo","year":"2021","unstructured":"Guo, Y. et al. Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity. Nat. Immunol. 22, 746\u2013756 (2021).","journal-title":"Nat. Immunol."},{"key":"77461_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.619195","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. IL-10 Enhances human natural killer cell effector functions via metabolic reprogramming regulated by mTORC1 signaling. Front. Immunol. 12, 619195 (2021).","journal-title":"Front. Immunol."},{"key":"77461_CR40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1126\/science.aal3535","volume":"356","author":"WKE Ip","year":"2017","unstructured":"Ip, W. K. E., Hoshi, N., Shouval, D. S., Snapper, S. & Medzhitov, R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science 356, 513\u2013519 (2017).","journal-title":"Science"},{"key":"77461_CR41","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nrm2153","volume":"8","author":"SJ Riedl","year":"2007","unstructured":"Riedl, S. J. & Salvesen, G. S. The apoptosome: signalling platform of cell death. Nat. Rev. Mol. Cell Biol. 8, 405\u2013413 (2007).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"77461_CR42","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.4049\/jimmunol.1501006","volume":"195","author":"CA Chougnet","year":"2015","unstructured":"Chougnet, C. A. et al. Loss of phagocytic and antigen cross-presenting capacity in aging dendritic cells is associated with mitochondrial dysfunction. J. Immunol. 195, 2624\u20132632 (2015).","journal-title":"J. Immunol."},{"key":"77461_CR43","doi-asserted-by":"publisher","unstructured":"Hu, Z. et al. Glycolysis drives STING signaling to facilitate dendritic cell antitumor function. J. Clin. Invest. 133, https:\/\/doi.org\/10.1172\/jci166031 (2023).","DOI":"10.1172\/jci166031"},{"key":"77461_CR44","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.it.2019.06.004","volume":"40","author":"P Giovanelli","year":"2019","unstructured":"Giovanelli, P., Sandoval, T. A. & Cubillos-Ruiz, J. R. Dendritic cell metabolism and function in tumors. Trends Immunol. 40, 699\u2013718 (2019).","journal-title":"Trends Immunol."},{"key":"77461_CR45","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1073\/pnas.1417620112","volume":"112","author":"EM Carrington","year":"2015","unstructured":"Carrington, E. M. et al. Prosurvival Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cells. Proc. Natl. Acad. Sci. USA 112, 4044\u20134049 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77461_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5957-x","volume":"19","author":"MJ Jo","year":"2019","unstructured":"Jo, M. J. et al. Genipin induces mitochondrial dysfunction and apoptosis via downregulation of Stat3\/mcl-1 pathway in gastric cancer. BMC Cancer 19, 739 (2019).","journal-title":"BMC Cancer"},{"key":"77461_CR47","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/ncb2488","volume":"14","author":"RM Perciavalle","year":"2012","unstructured":"Perciavalle, R. M. et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat. Cell Biol. 14, 575\u2013583 (2012).","journal-title":"Nat. Cell Biol."},{"key":"77461_CR48","first-page":"1123","volume":"52","author":"J List","year":"1992","unstructured":"List, J. et al. Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, gamma-interferon, and soluble interleukin 2 receptor (Mr 55,000 protein). Cancer Res. 52, 1123\u20131128 (1992).","journal-title":"Cancer Res."},{"key":"77461_CR49","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1749-6632.2009.05160.x","volume":"1182","author":"AR Chavez","year":"2009","unstructured":"Chavez, A. R. et al. Pharmacologic administration of interleukin-2. Ann. N. Y Acad. Sci. 1182, 14\u201327 (2009).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"77461_CR50","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg, S. A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192, 5451\u20135458 (2014).","journal-title":"J. Immunol."},{"key":"77461_CR51","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","volume":"18","author":"R Spolski","year":"2018","unstructured":"Spolski, R., Li, P. & Leonard, W. J. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat. Rev. Immunol. 18, 648\u2013659 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"77461_CR52","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1517\/14712598.3.5.725","volume":"3","author":"H Braat","year":"2003","unstructured":"Braat, H., Peppelenbosch, M. P. & Hommes, D. W. Interleukin-10-based therapy for inflammatory bowel disease. Expert Opin. Biol. Ther. 3, 725\u2013731 (2003).","journal-title":"Expert Opin. Biol. Ther."},{"key":"77461_CR53","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1053\/gast.2000.20229","volume":"119","author":"RN Fedorak","year":"2000","unstructured":"Fedorak, R. N. et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn\u2019s disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119, 1473\u20131482 (2000).","journal-title":"Gastroenterology"},{"key":"77461_CR54","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1124\/pr.55.2.4","volume":"55","author":"K Asadullah","year":"2003","unstructured":"Asadullah, K., Sterry, W. & Volk, H. D. Interleukin-10 therapy\u2013review of a new approach. Pharm. Rev. 55, 241\u2013269 (2003).","journal-title":"Pharm. Rev."},{"key":"77461_CR55","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.immuni.2014.03.012","volume":"40","author":"E Zigmond","year":"2014","unstructured":"Zigmond, E. et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity 40, 720\u2013733 (2014).","journal-title":"Immunity"},{"key":"77461_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101154","volume":"4","author":"YW Chang","year":"2023","unstructured":"Chang, Y. W. et al. A CSF-1R-blocking antibody\/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8(+) T cells. Cell Rep. Med. 4, 101154 (2023).","journal-title":"Cell Rep. Med."},{"key":"77461_CR57","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","volume":"27","author":"P Voabil","year":"2021","unstructured":"Voabil, P. et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat. Med. 27, 1250\u20131261 (2021).","journal-title":"Nat. Med."},{"key":"77461_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj9779","volume":"14","author":"P Kaptein","year":"2022","unstructured":"Kaptein, P. et al. Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors. Sci. Transl. Med. 14, eabj9779 (2022).","journal-title":"Sci. Transl. Med."},{"key":"77461_CR59","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/2326-6066.CIR-18-0622","volume":"7","author":"D Neri","year":"2019","unstructured":"Neri, D. Antibody-cytokine fusions: versatile products for the modulation of anticancer immunity. Cancer Immunol. Res. 7, 348\u2013354 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"77461_CR60","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","volume":"21","author":"ME Goebeler","year":"2024","unstructured":"Goebeler, M. E., Stuhler, G. & Bargou, R. Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat. Rev. Clin. Oncol. 21, 539\u2013560 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"77461_CR61","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1182\/blood.V98.7.2143","volume":"98","author":"S Fujii","year":"2001","unstructured":"Fujii, S., Shimizu, K., Shimizu, T. & Lotze, M. T. Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood 98, 2143\u20132151 (2001).","journal-title":"Blood"},{"key":"77461_CR62","doi-asserted-by":"publisher","first-page":"eadf4726","DOI":"10.1126\/sciimmunol.adf4726","volume":"10","author":"V Bhandarkar","year":"2025","unstructured":"Bhandarkar, V., Dinter, T. & Spranger, S. Architects of immunity: How dendritic cells shape CD8(+) T cell fate in cancer. Sci. Immunol. 10, eadf4726 (2025).","journal-title":"Sci. Immunol."},{"key":"77461_CR63","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen, C. S. et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576, 465\u2013470 (2019).","journal-title":"Nature"},{"key":"77461_CR64","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41590-022-01324-w","volume":"23","author":"R Wu","year":"2022","unstructured":"Wu, R. et al. Mechanisms of CD40-dependent cDC1 licensing beyond costimulation. Nat. Immunol. 23, 1536\u20131550 (2022).","journal-title":"Nat. Immunol."},{"key":"77461_CR65","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.yjmcc.2020.07.009","volume":"146","author":"AG Moyzis","year":"2020","unstructured":"Moyzis, A. G. et al. Mcl-1-mediated mitochondrial fission protects against stress but impairs cardiac adaptation to exercise. J. Mol. Cell Cardiol. 146, 109\u2013120 (2020).","journal-title":"J. Mol. Cell Cardiol."},{"key":"77461_CR66","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1016\/j.immuni.2021.11.004","volume":"54","author":"BS Hanna","year":"2021","unstructured":"Hanna, B. S. et al. Interleukin-10 receptor signaling promotes the maintenance of a PD-1(int) TCF-1(+) CD8(+) T cell population that sustains anti-tumor immunity. Immunity 54, 2825\u20132841 (2021).","journal-title":"Immunity"},{"key":"77461_CR67","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.4049\/jimmunol.165.9.5133","volume":"165","author":"S Rovero","year":"2000","unstructured":"Rovero, S. et al. DNA vaccination against rat her-2\/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB\/c mice. J. Immunol. 165, 5133\u20135142 (2000).","journal-title":"J. Immunol."},{"key":"77461_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2023.102282","volume":"4","author":"LM Roelofsen","year":"2023","unstructured":"Roelofsen, L. M. et al. Protocol for ex vivo culture of patient-derived tumor fragments. STAR Protoc. 4, 102282 (2023).","journal-title":"STAR Protoc."},{"key":"77461_CR69","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675\u2013678 (2020).","journal-title":"Nat. Biotechnol."},{"key":"77461_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77461-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77461-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77461-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:03:06Z","timestamp":1791975786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77461-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77461"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77461-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10767"}}